the World Ophthalmic Drugs Market Will Reach $20.9bn in 2014, According to a New Study on ASDReports

Thursday 7 August 2014, Amsterdam

The new report now available on ASDReports, predicts that the world market for ophthalmic drugs will reach $20.9bn in 2014. This forecast and others appear in Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies, published in June 2014.

Ophthalmic drugs are drugs used to treat eye diseases such as glaucoma, age-related macular degeneration (AMD), allergic conjunctivitis, and dry eye disease. This niche sector of the pharmaceutical industry is dominated by a small number of companies but retains high growth potential in some disease areas in 2014-2024. The ophthalmic drugs market has also been transformed in recent years by the impact of generic prostaglandin analogues for treating glaucoma, the challenge to Roche’s blockbuster Lucentis from Regeneron’s wet AMD drug, Eylea, and by Valeant Pharmaceuticals’ $8.7bn-acquisition of leading eye care company Bausch and Lomb.

Thomas Ling, a senior pharmaceutical and medical devices industry analyst said: “The ophthalmic drugs market is expected to grow strongly during 2014-2024. This growth will be driven by the increasing prevalence of many eye diseases, especially glaucoma, AMD and diabetic retinopathy, as well as the launch of new drugs and formulations to address the huge unmet need for treatments to prevent visual loss. We continue to note a trend towards increasing concentration of market share among fewer companies, with Santen’s acquisition of Merck’s remaining ophthalmic drugs in May 2014 and Valeant’s bid to acquire rival Allergan. Companies with truly innovative therapies for patients in this market can expect to reap great rewards; it will be interesting to see whether Novartis’s licensing deal with Ophthotech’s Fovista will disrupt the market for AMD treatments.”

This report provides revenue forecasts to 2024 for the world ophthalmic drugs market and leading submarkets. It forecasts sales for the glaucoma, retinal disorders, allergy/inflammatory/infective and dry eye segments of the market. The report also profiles ten leading companies in the ophthalmic drugs market – Allergan, Bayer, Merck & Co., Novartis, Pfizer, Regeneron, Roche, Santen, Senju and Valeant. It also discusses key marketed products, products in the development pipeline, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes interviews with industry experts regarding current market trends. The report also includes a Porter’s Five Forces analysis to understand the degree of competitiveness in this market.